

ds

Set	Items	Description
S1	196	I(N) 131
S2	293	I (N) 125
S3	134	S1 AND S2
S4	1364	C(N)14
S5	20	S3 AND S4
S6	73	S(W)35
S7	4	S5 AND S6
S8	210	P(N)32
S9	4	S7 AND S8
S10	62	P(N)33
S11	4	S9 AND S10
S12	1	S11 AND PY<=2001

? s label?  
S13 49361 LABEL?  
? s s5 and s13  
20 S5  
49361 S13  
S14 12 S5 AND S13  
? s s14 and 6  
12 S14  
3541758 6  
S15 12 S14 AND 6  
? s s15 and s8  
12 S15  
210 S8  
S16 4 S15 AND S8  
? t s16 and py<2001  
>>>'AND' not allowed in command  
? t s16 and py<2001  
>>>'AND' not allowed in command  
? s s16 and py<2001  
4 S16  
3482299 PY<2001  
S17 1 S16 AND PY<2001  
? t s17/3,k,ab/1

17/3,K,AB/1

DIALOG(R) File 340:CLAIMS(R)/US Patent  
(c) 2006 IFI/CLAIMS(R). All rts. reserv.

Dialog Acc No: 3330135 IFI Acc No: 0016245

IFI Publication Control No: 0016245

Document Type: C

**LOCALIZATION AND THERAPY OF NON-PROSTATIC ENDOCRINE CANCER WITH AGENTS  
DIRECTED AGAINST PROSTATE SPECIFIC ANTIGEN; IN VIVO METHOD FOR IMAGING  
BREAST AND OVARIAN CANCERS IN NON-PROSTATIC TISSUE OF A PATIENT**

Inventors: Diamandis Eleftherios P (CA); Redshaw Russell (CA)

Assignee: Nordion International Inc CA

Assignee Code: 33529

Attorney, Agent or Firm: Banner & Witcoff, Ltd.

Publication (No,Kind,Date), Applic (No,Date):

US 6068830 A 20000530 US 96569206 19960411

Calculated Expiration: 20170530

(Cited in 001 later patents)

**Document Type: CERTIFICATE OF CORRECTION**

Certificate of Correction Date: 20010522

Internat. Convention Pub(No,Date),Applic(No,Date): WO 9502424

**19950126** WO 94CA392 19940714

Section 371: 19960411

Section 102(e):19960411

Priority Applic(No,Date): GB 9314623 19930714

Abstract: It was discovered that prostate-specific antigen is produced by non-prostatic endocrine cancers. It was further discovered that non-prostatic endocrine cancers with steroid receptors can be stimulated with steroids to cause them to produce PSA either initially or at increased levels. This invention relates to the imaging of non-prostatic endocrine cancers by **labelled** biological binding units which bind to prostate-specific antigen in an imaging procedure, such as, radioimaging or magnetic resonance imaging. Further, the PSA-binding units may be constructed to deliver a toxic agent, such as a radioisotope, toxin or a drug to provide endocrine cancer therapy. Another aspect of the invention is passive immunotherapy against endocrine cancers by treatment with PSA-binding units.

Publication (No,Kind,Date), Applic (No,Date):

... **20000530**

...Internat. Convention Pub(No,Date),Applic(No,Date): **19950126**

Abstract: ...at increased levels. This invention relates to the imaging of non-prostatic endocrine cancers by **labelled** biological binding units which bind to prostate-specific antigen in an imaging procedure, such as...

Exemplary Claim:

...to prostate specific antigen produced by non-prostatic tissue of the patient, said antibodies being **labeled** with imaging agents; allowing said antibodies to incubate in vivo and bind prostate specific antigen

...

Non-exemplary Claims:

...3. The method of claim 1, wherein the antibodies are **labeled** with a radioisotope and the patient is imaged with a photoscanning device...

...Bi, 205 Bi, 206 Bi, 76 Br, 77 Br, 82 Br109 Cd, 47 CA, 11 C , 14 C , 36 Cl, 48 Cr, 51 Cr, 62 Cu, 64 Cu, 67 Cu, 165 Dy, 155...

...72 Ga, 198 Au, 3 H, 166 Ho, 111 In, 113m In, 115m In, 123 I , 125 I , 131 I , 189 Ir, 191m Ir, 192 Ir, 194 Ir, 52 Fe, 55 Fe, 59 Fe, 177 Lu, 15 O, 191m-191 OS, 109 Pd, 32 P , 33 P, 42 K, 226 Ra, 186 Re, 188 Re, 82m Rb, 153 Sm, 46...

...A method of claim 4, wherein the radioisotope is selected from the group consisting of: 131 I , 125 I , 111 In, 99m Tc, 90 Y, 186 Re, 153 Sm, 67 Ga, 201 Tl, 77...

... 6 . The method of claim 1, wherein the antibodies are **labeled** with a metal attached covalently to create a paramagnetic conjugate and the patient is imaged...

...7. A method of claim 6 , wherein the metal is selected from the group consisting of: gadolinium, terbium, tin, iron and

?

15/3,K,AB/2 (Item 1 from file: 340)  
DIALOG(R)File 340:CLAIMS(R)/US Patent  
(c) 2006 IFI/CLAIMS(R). All rts. reserv.

Dialog Acc No: 2614456 IFI Acc No: 9514714  
IFI Publication Control No: 9514714  
Document Type: C

**MARKERS FOR INVASIVE PROSTATIC NEOPLASIA; USING NON-PROSTATIC TISSUE FOR ISOLATION OF GENES**

Inventors: Dooley Thomas P (US); Thompson Timothy C (US)

Assignee: Baylor College of Medicine

Assignee Code: 06345

Attorney, Agent or Firm: Baker & Botts

Publication (No,Kind,Date), Applic (No,Date):

US 5424192 A 19950613 US 9338491 19930329

Calculated Expiration: 20130329

(Cited in 001 later patents)

Priority Applic(No,Date): US 9338491 19930329

Abstract: This invention is directed to the identification, isolation and use of nonprostate derived markers, such as markers derived from the seminal vesicles, and antibodies which recognize these markers in the diagnosis of invasive prostatic neoplasia, to diagnostic aids for screening biological samples for evidence of invasive prostatic neoplasia, and to methods for the use of these diagnostic aids.

Publication (No,Kind,Date), Applic (No,Date):

... 19950613

Non-exemplary Claims:

...label is selected from the group consisting of a radio isotope, a stable isotope, a **fluorescent** chemical, a luminescent chemical, a metal, an electrical charge, an enzyme, a chromatic chemical, a...

...12. The method of claim 1 which is an EIA, an **ELISA**, a **Western blot**, a **slot blot**, or a RIA...label is selected from the group consisting of a radio isotope, a stable isotope, a **fluorescent** chemical, a luminescent chemical, a metal, an electrical charge, an enzyme, a chromatic chemical, a...

...30. The method of claim 15 which is an EIA, an **ELISA**, a **Western blot**, a **slot blot**, or a RIA...

?

, a slot blot , or a RIA...  
? ds

Set	Items	Description
S1	500483	WESTERN
S2	194505	ELISA
S3	21481	S1 AND S2
S4	4266	SLOT(W)BLOT??
S5	29	S3 AND S4
S6	19	RD (unique items)
S7	10	S6 AND PY<=2001
S8	964	IMMUNHISTOCHEMI?
S9	0	S7 AND S8
S10	479376	ELECTROPHORESIS
S11	0	S7 AND S8
? s radioactive		
	S12 116941	RADIOACTIVE
? s s7 and s12		
	10	S7
	116941	S12
	S13 0	S7 AND S12
? s fluorescent or chromomorphpic		
	374269	FLUORESCENT
	5	CHROMOMORPHIC
	S14 374273	FLUORESCENT OR CHROMOMORPHIC
? s s7 and s14		
	10	S7
	374273	S14
	S15 2	S7 AND S14
? t s15/3,k,ab/1-2		

15/3,K,AB/1 (Item 1 from file: 155)  
DIALOG(R) File 155:MEDLINE(R)  
(c) format only 2006 Dialog. All rts. reserv.

10351591 PMID: 7760479

Experimental infection of northern bobwhite quail with *Borrelia burgdorferi*.

9/3,K,AB/2 (Item 2 from file: 155)  
DIALOG(R)File 155:MEDLINE(R)  
(c) format only 2006 Dialog. All rts. reserv.

10794767 PMID: 8565293

**Expression of mammalian 60-kD heat shock protein in the joints of mice with pristane-induced arthritis.**

Barker R N; Wells A D; Ghoraishian M; Easterfield A J; Hitsumoto Y; Elson C J; Thompson S J

Department of Pathology and Microbiology, University of Bristol, UK.

Clinical and experimental immunology (ENGLAND) Jan 1996 , 103 (1)  
p83-8, ISSN 0009-9104--Print Journal Code: 0057202

Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

Previous work has indicated that autoimmunity to the mammalian 60-kD heat shock protein (hsp60) may be necessary for the development of pristane-induced arthritis (PIA), a murine model of rheumatoid arthritis. To characterize the expression of hsp60 in murine joints, immunoblots of joint extracts and frozen histological sections prepared from normal or arthritic mice were probed with the hsp60-specific MoAb 4B989. Hsp60 could be detected in the joints of mice with PIA by both techniques, and was seen to be localized within the inflamed pannus using **immunohistochemistry**. Immunoblotting revealed that lower concentrations of hsp60 are also present in normal mouse joints, and that the level of expression increases with age, in parallel with greater susceptibility to PIA. In other studies, it was demonstrated that the titres of serum IgG antibodies reactive with the related mycobacterial hsp65, and the in vitro responsiveness of splenic T cells to hsp65, are both elevated in older mice. It is considered that the results are consistent with the hypothesis that PIA develops following environmental priming with mycobacterial hsp65, and the targeting of cross-reactive T cells to self-hsp60 in the joints.

... 1996 ,

... PIA by both techniques, and was seen to be localized within the inflamed pannus using **immunohistochemistry**. Immunoblotting revealed that lower concentrations of hsp60 are also present in normal mouse joints, and

...

; Age Factors; Animals; Arthritis--etiology--ET; Arthritis--immunology--IM; Chaperonin 60--analysis--AN; **Electrophoresis** , Polyacrylamide Gel; Immunoblotting; Immunohistochemistry; Knee Joint--immunology--IM; Mice; Mice, Inbred CBA; Research Support, Non...

19/3,K,AB/3 (Item 3 from file: 155)  
DIALOG(R)File 155:MEDLINE(R)  
(c) format only 2006 Dialog. All rts. reserv.

08692207 PMID: 1705378

**[Immunohistochemistry of cytokeratin expression in human blood vessel endothelia with special reference to synovial connective tissue]**

**Immunohistochemische** Untersuchungen zur Cytokeratin-Expression in menschlichen Gefassendothelien unter besonderer Berucksichtigung des Gelenkbindegewebes.

Stosiek P; Kasper M; Conrad K

Institut fur Pathologie, Bakteriologie und Serologie,

Bezirkskrankenhauses Gorlitz, DDR.

Acta histochemica (GERMANY) 1990 , 89 (1) p61-6, ISSN 0065-1281--  
Print Journal Code: 0370320

Publishing Model Print

Document type: Journal Article ; English Abstract

Languages: GERMAN

Main Citation Owner: NLM

Record type: MEDLINE; Completed

41 tissue samples derived from the synovia, epidermis, and other organs were studied immunohistochemically using monoclonal antibodies against intermediate filaments. We observed a coexpression of cytokeratin and vimentin in endothelia of small blood vessels preferably enriched in locations with enhanced fluid transport and processes of ultrafiltration via endothelial cells (synovial tissue, ganglion). The presence of cytokeratin 18 in endothelial cells has been confirmed by gel-electrophoresis with immunoblotting. In many cases, the coexpression of cytokeratin and vimentin reveals a correlation to the secretion of simply and epithelially differentiated cells as could be demonstrated for other tissue structures in previous studies. The increased expression of cytokeratins in endothelia of ganglion walls is discussed in relation to synovia-like misfunction of the joint connective tissue.

**Immunhistochemische** Untersuchungen zur Cytokeratin-Expression in menschlichen Gefassendothelien unter besonderer Berucksichtigung des Gelenkbindegewebes.

... 1990 ,

...tissue, ganglion). The presence of cytokeratin 18 in endothelial cells has been confirmed by gel-electrophoresis with immunoblotting. In many cases, the coexpression of cytokeratin and vimentin reveals a correlation to...

; Antibodies, Monoclonal--diagnostic use--DU; Connective Tissue--anatomy and histology--AH; **Electrophoresis** , Polyacrylamide Gel; Endothelium, Vascular--anatomy and histology--AH; English Abstract; Humans; Immunoblotting; Immunoenzyme Techniques; Immunohistochemistry...

19/3,K,AB/4 (Item 4 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2006 Dialog. All rts. reserv.

07182690 PMID: 2431556

**[A simple method of preparation of keratin filaments and production of a polyclonal broad-spectrum anti-cytokeratin antiserum for immunohistochemical application in fixed and unfixed epithelial tissues]**

Ein einfaches Verfahren der Preparation von Keratinfilamenten und Herstellung eines polyklonalen Breitspektrum-Anti-Zytokeratin-Antiserums fur die immunhistochemische Anwendung bei fixierten und unfixierten epithelialen Geweben.

Dopel S H; Topel K; Schulz J; Schneider W; Ladhoff A; Naumann W

Zentralblatt fur allgemeine Pathologie und pathologische Anatomie (GERMANY, EAST) 1986 , 132 (3) p197-207, ISSN 0044-4030--Print  
Journal Code: 9105593

Publishing Model Print

Document type: Journal Article ; English Abstract

Languages: GERMAN

Main Citation Owner: NLM

Record type: MEDLINE; Completed

Rabbits were immunized with 10 nm filaments of a mixture of cytokeratins

which has been isolated from human heel callus material and reconstituted to filaments in vitro. The antisera to keratins (ASK) have been tested histologically at fixed and unfixed tissue samples by means of the indirect immunofluorescence and PAP technique. The ASK recognized specifically only the epithelial cells of skin, of the mucous membranes of mouth and digestive tract, of salivary glands, sweat gland and mammary gland, but did not react with hepatocytes or kidney cells. The following tumors, tested till now, reacted with the antikeratin antisera: epithelial and lymphoepithelial carcinomas of skin, mouth and digestive tract, carcinomas of salivary glands, mammary gland and thyroid gland, adamantinoma, basalioma of skin, and metastases from carcinomas.

... Verfahren der Präparation von Keratinfilamenten und Herstellung eines polyklonalen Breitspektrum-Anti-Zytokeratin-Antiserums für die immunhistochemische Anwendung bei fixierten und unfixierten epithelialen Geweben.

... 1986 ,  
; Animals; **Electrophoresis** , Polyacrylamide Gel; English Abstract; Epithelial Cells; Fluorescent Antibody Technique; Gastric Mucosa--analysis --AN; Gastric Mucosa...

19/3,K,AB/5 (Item 5 from file: 155)  
DIALOG(R) File 155:MEDLINE(R)  
(c) format only 2006 Dialog. All rts. reserv.

06588392 PMID: 6099008

? s electrophoresis  
     S1    6696  ELECTROPHORESIS  
 ? s histochem?  
     S2    139  HISTOCHEM?  
 ? s s1 and s2  
         6696  S1  
         139  S2  
     S3        8  S1 AND S2  
 ? s s3 and py<=2001  
         8  S3  
     3721772  PY<=2001  
     S4        4  S3 AND PY<=2001  
 ? t s4/3,k,ab/1-4

**4/3,K,AB/1**

DIALOG(R) File 340:CLAIMS(R)/US Patent  
 (c) 2006 IFI/CLAIMS(R). All rts. reserv.

Dialog Acc No: 2607666  IFI Acc No: 9512909  
 IFI Publication Control No: 9512909  
 Document Type: C

**METHOD FOR SCREENING FOR CARDIOMYOPATHY; MEASURING BINDING OF ANTIBODY TO DYSTROPHIN-ASSOCIATED GLYCOPROTEIN**

Inventors: Campbell Kevin P (US)  
 Assignee: Iowa, University of Research Foundation  
 Assignee Code: 00820  
 Attorney, Agent or Firm: Farrell, Kevin M  
 Publication (No,Kind,Date), Applic (No,Date):  
 US 5418139  A  **19950523**  US 9316126  19930210  
 Calculated Expiration: 20130210  
     (Cited in 002 later patents)  
 Priority Applic(No,Date): US 9316126  19930210

Abstract: Disclosed herein are methods for screening for primary cardiomyopathy. The methods are preferably immunological methods in which the level of binding of a monoclonal or polyclonal antibody to a 50 kD glycoprotein component of a mammalian muscle tissue is determined. This level of binding is compared to the level of binding observed when non-dystrophic tissue is treated in an otherwise identical manner. A substantial reduction in the level of binding to the 50 kD glycoprotein in the experimental mammalian muscle tissue has been determined to be a screen for primary cardiomyopathy.

Publication (No,Kind,Date), Applic (No,Date):  
 ... **19950523**

Non-exemplary Claims:

...mammal comprising the steps of: a) providing a cardiac muscle tissue biopsy sample suitable for **histochemical** analysis; b) contacting the cardiac muscle tissue biopsy sample with an antibody which binds to...  
 ...from the mammal; b) separating the components of the solubilized muscle cell membranes by gel **electrophoresis**; c) transferring the separated components from step b) to a solid support; d) contacting the...

**4/3,K,AB/2**

DIALOG(R) File 340:CLAIMS(R)/US Patent  
 (c) 2006 IFI/CLAIMS(R). All rts. reserv.



Dialog Acc No: 2439365 IFI Acc No: 9402258

IFI Publication Control No: 9402258

Document Type: C

**SERUM GROWTH FACTOR; GLYCOSYLATED ALBUMIN GROWTH FACTOR FOR TISSUE TREATMENT**

Inventors: Dehazya Philip (US)

Assignee: Alliance Pharmaceutical Corp

Assignee Code: 23198

Attorney, Agent or Firm: Knobbe, Martens, Olson & Bear

Publication (No,Kind,Date), Applic (No,Date):

US 5281582 A 19940125 US 92843920 19920227

Calculated Expiration: 20120227

**Document Type: EXPIRED**

Priority Applic(No,Date): US 92843920 19920227

Abstract: A novel glycosylated form of albumin designated EGA and isolated from biological fluids is further characterized by its cell growth promoting activity. A process of isolation of human or bovine glycosylated albumin is described. The EGA fractions have been identified by serological **histochemical** and biological assays as well as lectin reactivity. The growth-promoting effect of EGA is directed to various transformed cell lines and primary cells of mammalian origin. Hepatoma cells have been found to produce EGA, in vitro. Novel compositions of EGA containing media are provided for cell, tissue or organ culture.

Publication (No,Kind,Date), Applic (No,Date):

... 19940125

Abstract: ...human or bovine glycosylated albumin is described. The EGA fractions have been identified by serological **histochemical** and biological assays as well as lectin reactivity. The growth-promoting effect of EGA is...

Non-exemplary Claims:

...precipitation; ion exchange chromatography; gel filtration; molecular sieve filtration or dialysis; lectin affinity chromatography; gel **electrophoresis** ; and a bioassay for selecting fractions of the glycosylated albumin with growth promoting activity.

**4/3,K,AB/3**

DIALOG(R) File 340:CLAIMS(R)/US Patent

(c) 2006 IFI/CLAIMS(R). All rts. reserv.

Dialog Acc No: 2432757 IFI Acc No: 9400109

IFI Publication Control No: 9400109

Document Type: C

**CETYLTRIMETHYLAMMONIUM BROMIDE GEL ELECTROPHORESIS ; GEL WITH CATIONIC SURFACTANT**

Inventors: Akins Robert E Jr (US); Tuan Rocky S (US)

Assignee: Jefferson, Thomas University

Assignee Code: 06943

Attorney, Agent or Firm: Woodcock Washburn Kurtz Mackiewicz & Norris

Publication (No,Kind,Date), Applic (No,Date):

US 5275708 A 19940104 US 92853963 19920320

Calculated Expiration: 20120320

(Cited in 008 later patents)

Priority Applic(No,Date): US 92853963 19920320

Abstract: A discontinuous polyacrylamide and agarose gel **electrophoresis** system is provided which allows the fine separation of proteins based on molecular weight with the concomitant retention of native enzymatic activity. This system, referred to as the CAT gel, uses the cationic detergent CTAB, and includes a stacking gel based on a zwitterion such as arginine and a buffer such as tricine. The CAT gel system allows specific enzyme **histochemical** detection and localization of proteins after gel **electrophoresis**. This system stacked and separated a broad range of proteins into discrete bands which migrate as a linear function of log Mr. The effect of CTAB solubilization on the activity of several proteins is also shown. Proteins separated by CAT **electrophoresis** maintain high levels of native enzymatic activity, and may be detected **histochemically** in situ.

**CETYLTRIMETHYLAMMONIUM BROMIDE GEL ELECTROPHORESIS ;**

Publication (No,Kind,Date), Applic (No,Date):

... 19940104

Abstract: A discontinuous polyacrylamide and agarose gel **electrophoresis** system is provided which allows the fine separation of proteins based on molecular weight with...

...as arginine and a buffer such as tricine. The CAT gel system allows specific enzyme **histochemical** detection and localization of proteins after gel **electrophoresis**. This system stacked and separated a broad range of proteins into discrete bands which migrate...  
...CTAB solubilization on the activity of several proteins is also shown. Proteins separated by CAT **electrophoresis** maintain high levels of native enzymatic activity, and may be detected **histochemically** in situ.

Exemplary Claim:

1. A discontinuous gel **electrophoresis** system comprising a first and second electrode; a separation gel matrix located between the electrodes  
...

Non-exemplary Claims:

- ...4. A method for performing a discontinuous gel **electrophoresis**, comprising: (a) providing an **electrophoresis** system having a first and second electrode; a separation gel matrix, located between the first...

**4/3,K,AB/4**

DIALOG(R) File 340:CLAIMS(R)/US Patent

(c) 2006 IFI/CLAIMS(R). All rts. reserv.

Dialog Acc No: 1896666 IFI Acc No: 8821966

IFI Publication Control No: 8821966

Document Type: C

**DIAGNOSTIC METHOD FOR DETECTION OF NEURAL CREST DISEASE; USING ANTIBODIES SPECIFIC FOR HUMAN NERVE GROWTH FACTOR RECEPTORS**

Inventors: HERLYN MEENHARD (US); KOPROWSKI HILARY (US); ROSS ALONZO (US)

Assignee: WISTAR INSTITUTE OF ANATOMY AND BIOLOGY THE

Assignee Code: 92890

Attorney, Agent or Firm: Banner, Birch, McKie and Beckett

Publication (No,Kind,Date), Applic (No,Date):

US 4786593 A 119881122 US 85723760 19850416

Calculated Expiration: 20051122

(Cited in 002 later patents) Document Type: EXPIRED

Priority Applic(No,Date): US 85723760 19850416

Abstract: It has been determined that nerve growth factor binds to a cell surface protein of human neural crest origin having a molecular weight of about 75,000 daltons. New monoclonal antibodies specifically immunoprecipitate these receptor molecules, and also inhibit binding of the hormone to the receptor. These monoclonal antibodies show significantly higher reactivity with primary and metastatic melanoma cell lines than with melanocytes. The antibodies are used in a diagnostic method for **histochemical** detection of human neural crest disease.

Publication (No,Kind,Date), Applic (No,Date):

... 19881122

Abstract: ...melanoma cell lines than with melanocytes. The antibodies are used in a diagnostic method for **histochemical** detection of human neural crest disease.

Exemplary Claim:

...RECEPTORS HAVING AN APPARENT MOLECULAR WEIGHT OF ABOUT 75,000 DALTONS BY SDS-POLYACRYLAMIDE GEL **ELECTROPHORESIS** , AND DETERMINING THE CONCENTRATION OF SAID ANTIBODY BOUND TO SAID CELLS IN THE CYTOPLASM AND

...

?

File 155:MEDLINE(R) 1950-2006/Jul 19  
 (c) format only 2006 Dialog  
 File 55:Biosis Previews(R) 1993-2006/Jul W3  
 (c) 2006 The Thomson Corporation  
 File 34:SciSearch(R) Cited Ref Sci 1990-2006/Jul W2  
 (c) 2006 The Thomson Corp  
 File 434:SciSearch(R) Cited Ref Sci 1974-1989/Dec  
 (c) 2006 The Thomson Corp

Set	Items	Description
---	-----	-----
? s	phycolipoprotein	
S1	0	PHYCOLIPOPTEIN
? s	phycolipoprotein	
S2	0	PHYCOLIPOPTEIN
? b	155 55 scisearch 340	
	19jul06 15:38:35	User231882 Session D1666.8
	\$0.24	0.070 DialUnits File155
\$0.24	Estimated cost	File155
	\$0.62	0.105 DialUnits File55
\$0.62	Estimated cost	File55
	\$0.82	0.035 DialUnits File34
\$0.82	Estimated cost	File34
	\$2.47	0.105 DialUnits File434
\$2.47	Estimated cost	File434
	OneSearch, 4 files,	0.316 DialUnits FileOS
\$0.26	TELNET	
\$4.41	Estimated cost	this search
\$6.37	Estimated total session cost	0.425 DialUnits

SYSTEM:OS - DIALOG OneSearch  
 File 155:MEDLINE(R) 1950-2006/Jul 19  
 (c) format only 2006 Dialog  
 File 55:Biosis Previews(R) 1993-2006/Jul W3  
 (c) 2006 The Thomson Corporation  
 File 34:SciSearch(R) Cited Ref Sci 1990-2006/Jul W2  
 (c) 2006 The Thomson Corp  
 File 434:SciSearch(R) Cited Ref Sci 1974-1989/Dec  
 (c) 2006 The Thomson Corp  
 File 340:CLAIMS(R)/US Patent 1950-06/Jul 13  
 (c) 2006 IFI/CLAIMS(R)

**\*File 340: IPCR/8 classification codes now searchable in 2006 records.**  
 For important information about IC=index changes, see HELP NEWSIPCR.

Set	Items	Description
---	-----	-----
? s	phycolipoprotein	
S1	2	PHYCOLIPOPTEIN
? s	tetrarhodamine(w)isothiocyanate	
	8	TETRARHODAMINE
	26716	ISOTHIOCYANATE
S2	7	TETRARHODAMINE(W)ISOTHIOCYANATE
? rd		

>>>Duplicate detection is not supported for File 340.

>>>Records from unsupported files will be retained in the RD set.  
 S3 6 RD (unique items)

? s s3 and py<2001

Processing

Processing

6 S3

39900068 PY<2001

S4 2 S3 AND PY<2001

? t s4/3,k,ab/1-2

4/3,K,AB/1 (Item 1 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2006 Dialog. All rts. reserv.

08218597 PMID: 2806214

**Antigen-specific electrophoretic cell separation for immunological investigations.**

Hansen E; Wustrow T P; Hannig K

Department of Anesthesiology, University of Regensburg Federal Republic of Germany.

Electrophoresis (GERMANY, EAST) Aug-Sep 1989 , 10 (8-9) p645-52,  
ISSN 0173-0835--Print Journal Code: 8204476

Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

Preincubation of human blood lymphocytes with cell surface antigen specific antibodies under non-capping conditions reduces the electrophoretic mobility of the corresponding lymphocyte subpopulation. Antigen-positive and antigen-negative cells can be separated by free flow electrophoresis with high yield, purity and viability. The use of fluorescence-labelled second antibodies augments the induced decrease in net surface charge density, and allows rapid detection of antigen-positive cells in the fractions of electrophoresis. Carrier-free cell electrophoresis of human peripheral blood lymphocytes after reaction with anti-IgM-antibody or the monoclonal antibodies OKT4 or OKT8, and sandwich staining with **tettrarhodamine isothiocyanate** -labelled anti-IgG resulted in the large-scale separation of high pure human B and T lymphocyte subpopulations. Their functional integrity was shown in assays of lymphocyte transformation and of antigen-specific induction and regulation of antibody synthesis in vitro. These separate lymphocyte subpopulations are useful tools for immunological investigations. While, for instance, the effects of drugs on human lymphocytes are obscured by coincident changes in cell composition of the peripheral blood tested that do not by themselves reflect whole body immunocompetence, the cell separation and in vitro assays at a defined cell number and cell composition allow the recording of quantitative changes in the function of different cell subpopulations. We studied the influence of the anesthetic thiopental on separated human lymphocyte subsets. In both polyclonal lectin stimulation and in vitro antibody production, thiopental exhibited a noncytotoxic suppression of lymphocyte functions. B-Cells, T-helper and T-suppressor cells were equally affected and showed the same dose response. (ABSTRACT TRUNCATED AT 250 WORDS)

... 1989 ,

... with anti-IgM-antibody or the monoclonal antibodies OKT4 or OKT8, and sandwich staining with **tettrarhodamine isothiocyanate** -labelled anti-IgG resulted in the large-scale separation of high pure human B and...

4/3,K,AB/2 (Item 1 from file: 55)  
DIALOG(R)File 55:Biosis Previews(R)  
(c) 2006 The Thomson Corporation. All rts. reserv.

0008715863 BIOSIS NO.: 199395018129

**Improved indirect fluorescence immunocytochemical method using counterstains**

AUTHOR: Newkirk Robert F (Reprint); Mack Janea  
AUTHOR ADDRESS: Dep. Biol. Sci., Tenn. State Univ., Nashville, Tenn.  
37209-1561, USA\*\*USA  
JOURNAL: Biotechniques 13 (4): p536-538 1992  
ISSN: 0736-6205  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

ABSTRACT: Immunocytochemistry in recent years has provided powerful tools for research in neurobiology. One of the more popular techniques is the indirect fluorescence technique in which fluorescein isothiocyanate (FITC) or **tetrarhodamine isothiocyanate** (TRITC) is used. Although widely used, this technique has two disadvantages: (1) localization may be difficult in relation to background morphology, and (2) the fluorescence fades. The study reported here describes a modification of an indirect immunocytochemical technique using FITC, TRITC and 7-amino-4-methyl-coumarin-3-acetic acid (AMCA) which enhances localization and significantly prolongs fluorescence. Evans blue was used as a counterstain. The results show that FITC and AMCA stained cells are seen against a background of clearly distinguishable cells after counterstaining with Evans blue. However, Evans blue is not compatible with TRITC. In addition, the fluorescence life of the FITC is extended from several days to several weeks with Evans blue. These results clearly indicate that Evans blue can be used to improve indirect fluorescence immunocytochemical techniques.

1992

...ABSTRACT: the more popular techniques is the indirect fluorescence technique in which fluorescein isothiocyanate (FITC) or **tetrarhodamine isothiocyanate** (TRITC) is used. Although widely used, this technique has two disadvantages: (1) localization may be...

DESCRIPTORS:

MISCELLANEOUS TERMS: ... **TETRARHODAMINE ISOTHIOCYANATE** ;  
? log off

19jul06 15:42:20 User231882 Session D1666.9  
\$3.57 1.049 DialUnits File155  
\$0.22 1 Type(s) in Format 4 (UDF)  
\$0.22 1 Types  
\$3.79 Estimated cost File155  
\$1.67 0.282 DialUnits File55  
\$2.05 1 Type(s) in Format 4 (UDF)  
\$2.05 1 Types  
\$3.72 Estimated cost File55  
\$9.57 0.408 DialUnits File34  
\$9.57 Estimated cost File34  
\$9.36 0.399 DialUnits File434  
\$9.36 Estimated cost File434  
\$13.73 0.784 DialUnits File340  
\$13.73 Estimated cost File340

OneSearch, 5 files, 2.923 DialUnits FileOS  
\$1.06 TELNET  
\$41.23 Estimated cost this search  
\$47.60 Estimated total session cost 3.348 DialUnits

Logoff: level 05.12.03 D 15:42:20

You are now logged off

s phycoliporotein  
S1 0 PHYCOLIPOROTEIN  
? s phycolipoprotein  
S2 2 PHYCOLIPOPROTEIN  
? s tetrarhodamine(w)isothiocyanate  
3 TETRARHODAMINE  
1957 ISOTHIOCYANATE  
S3 3 TETRARHODAMINE(W) ISOTHIOCYANATE  
? t s2/3,k,ab/1-2

**2/3,K,AB/1**

DIALOG(R)File 340:CLAIMS(R)/US Patent  
(c) 2006 IFI/CLAIMS(R). All rts. reserv.

Dialog Acc No: 10825228 IFI Acc No: 2005-0063942  
IFI Publication Control No: 2005-0063942 IFI Chemical Acc No: 2005-0014866  
Document Type: C

**METHODS FOR PREDICTING SENSITIVITY OF TUMORS TO ARGININE DEPRIVATION**

Inventors: Clark Mike A (US); Ensor Charles Mark (US); Holtsberg Frederick Wayne (US)

Assignee: Unassigned Or Assigned To Individual

Assignee Code: 68000

Probable Assignee: Phoenix Pharmacologics Inc

Attorney, Agent or Firm: WOODCOCK WASHBURN LLP, ONE LIBERTY PLACE, 46TH FLOOR, 1650 MARKET STREET, PHILADELPHIA, PA, 19103, US

Publication (No,Kind,Date), Applic (No,Date):

US 20050063942 A1 20050324 US 2001775693 20010202

Priority Applic(No,Date): US 2001775693 20010202

Abstract: The present invention provides methods for determining which cancer patients are susceptible to arginine depletion therapy and methods for treating cancer. The present invention also provides methods for predicting the appropriateness of arginine deprivation therapy for a cancer patient. The methods generally comprise obtaining a tumor sample from the cancer patient and detecting the presence or absence of evidence of urea cycle enzyme expression in the tumor sample. The absence of evidence of urea cycle enzyme expression in the tumor sample is indicative of a cancer patient who is a candidate for arginine deprivation therapy, and the presence of evidence of urea cycle enzyme expression in said tumor sample is indicative of a cancer patient who is not a candidate for arginine deprivation therapy. Prior to, simultaneous with, or after testing the tumor sample, the method further comprises the steps of obtaining a non-cancerous sample from the cancer patient and detecting the presence or absence of evidence of urea cycle enzyme expression in the non-cancerous sample, wherein the absence of evidence of urea cycle enzyme expression in the noncancerous sample and absence of evidence of urea cycle enzyme expression in the tumor sample is indicative of a cancer patient who is not a good candidate for arginine deprivation therapy, the presence of evidence of urea cycle enzyme expression in the non-cancerous sample and the absence of evidence of urea cycle enzyme expression in the tumor sample is indicative of a cancer patient who is a good candidate for arginine deprivation therapy, and the presence of evidence of urea cycle enzyme expression in the tumor sample is indicative of a cancer patient who is not a candidate for arginine deprivation therapy.

**Non-exemplary Claims:**

...34. The method of claim 31 wherein said detectable label is fluorescein, **phycolipoprotein**, or tetrarhodamine isothiocyanate...



2/3,K,AB/2

DIALOG(R) File 340:CLAIMS(R)/US Patent  
(c) 2006 IFI/CLAIMS(R). All rts. reserv.

Dialog Acc No: 3391020 IFI Acc No: 0031485  
IFI Publication Control No: 0031485  
Document Type: C

**METHOD FOR DETECTING CANCERS; DIAGNOSING PROLIFERATION DEFECTS BY SCREENING  
FOR SPECIFIC ANTIGENS ON CELL SURFACE; INCUBATING SAMPLE WITH HUMANIZED  
ANTIBODY AND MONITORING BINDING OF ANTIBODY TO ANTIGENS ON SURFACE OF  
CELLS, BINDING INDICATES DEFECTIVE PROLIFERATION**

Inventors: Carr Francis Joseph (GB); Garin-Chesa Pilar (DE); Harris William  
Joseph (GB); Old Lloyd J (US); Rettig Wolfgang J (DE); Wallace Thomas  
Paul (GB)

Assignee: Ludwig Institute for Cancer Research  
Assignee Code: 28349

Attorney, Agent or Firm: Fulbright & Jaworski, LLP

Publication (No,Kind,Date), Applic (No,Date):

US 6124106 A 20000926 US 99266119 19990310

Calculated Expiration: 20140308

Priority Applic(No,Date): US 99266119 19990310; US 94207996  
19940308; US 96760840 19961205

Abstract: The invention provides for the production of several humanized murine antibodies specific for the antigen LK26, which is recognized by the murine antibody LK26. This antigen is expressed in all choriocarcinoma, teratocarcinoma and renal cancer cell lines whereas it is not expressed on cell lines of leukaemias, lymphomas, neuroectodermally-derived and epithelial tumour cell lines (excepting a small subset of epithelial cell lines). Furthermore, whereas renal cancer cell lines express the LK26 antigen, normal renal epithelial cells do not. Similarly, with the exception of the trophoblast, all normal adult and fetal tissues tested are negative for the LK26 phenotype. The invention also provides for numerous polynucleotide encoding humanized LK26 specific antibodies, expression vectors for producing humanized LK26 specific antibodies, and host cells for the recombinant production of the humanized antibodies. The invention also provides methods for detecting cancerous cells (in vitro and in vivo) using humanized LK26 specific antibodies. Additionally, the invention provides methods of treating cancer using LK26 specific antibodies.

Non-exemplary Claims:

...10. The method of claim 8, wherein said detectable label is  
fluorescein, **phycolipoprotein**, or tetraethylrhodamine...

?

**Isolation and characterization of argininosuccinate synthetase from human liver.**

O'Brien W E

Biochemistry (UNITED STATES) Nov 27 1979 , 18 (24) p5353-6, ISSN 0006-2960--Print Journal Code: 0370623

Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

This communication describes the purification and characterization of **argininosuccinate synthetase** from human liver. By numerous criteria including electrophoresis in sodium dodecyl sulfate containing gels, electrophoresis in nondissociating gels, and analytical ultracentrifugation, the protein is homogeneous at a specific activity of 4.2  $\mu\text{mol}/(\text{min mg})$  assayed at 37 degrees C in the direction of argininosuccinate synthesis. The enzyme has a molecular weight of 183,000, as determined by gel filtration. Electrophoresis in the presence of sodium dodecyl sulfate yielded a single band migrating with an  $R_f$  corresponding to 43,000 daltons. Thus, the enzyme is considered to contain four subunits of identical molecular weight. The  $s_{20,w}$  of the enzyme is 8.2 S. **Antibodies** were prepared in rabbits directed against the purified protein. These **antibodies** react specifically with **argininosuccinate synthetase**, as determined by electrophoretic analysis of the immunoadsorbed product from crude extracts of human liver. The human enzyme has very similar properties to those published for the beef and rat liver enzymes.

**Isolation and characterization of argininosuccinate sy**

Argininosuccinate synthetase and argininosuccinate lyase are  
localized around mitochondria: an immunocytochemical study.

Cohen N S; Kuda A

Department of Biochemistry and Molecular Biology, University of Southern  
California School of Medicine, Los Angeles, 90033, USA.

Journal of cellular biochemistry (UNITED STATES) Mar 1 1996 , 60 (3)  
p334-40, ISSN 0730-2312--Print Journal Code: 8205768

Contract/Grant No.: GM44638; GM; NIGMS

```

s arginosuccinate (w)synthetase
      135  ARGINOSUCCINATE
      89154  SYNTHETASE
s1      83  ARGINOSUCCINATE (W)SYNTHETASE
? s antibod?
      S2 1658215  ANTIBOD?
? s s1 and s2
      83  S1
      1658215  S2
      S3      3  S1 AND S2
? rd

```

>>>Duplicate detection is not supported for File 340.

>>>Records from unsupported files will be retained in the RD set.

```

      S4      3  RD  (unique items)
? s s4 and py<=2001
Processing

```

```

      3  S4
      42201070  PY<=2001
      S5      0  S4 AND PY<=2001
? s argininosuccinate (w)synthetase
      2549  ARGININOSUCCINATE
      89154  SYNTHETASE
      S6      1229  ARGININOSUCCINATE (W)SYNTHETASE
? s s6 and s2
      1229  S6
      1658215  S2
      S7      39  S6 AND S2
? rd

```

>>>Duplicate detection is not supported for File 340.

>>>Records from unsupported files will be retained in the RD set.

```

      S8      28  RD  (unique items)
? s s8 and py<2001
Processing

```

```

      28  S8
      39900068  PY<2001
      S9      20  S8 AND PY<2001
? t s9/3,k,ab/1-20

```

```

9/3,K,AB/1      (Item 1 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2006 Dialog. All rts. reserv.

```

12994428 PMID: 11153906

Identification of two novel mutations in the SLC25A13 gene and detection of seven mutations in 102 pa